Zhejiang Innoforce Pharmaceuticals
PrivateLast Round
Series A
Dec 6, 2021
Total Funding Raised
$156.6M
Company Overview
Zhejiang Innoforce Pharmaceuticals operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series A round in December 2021.
Zhejiang Innoforce Pharmaceuticals is a biopharmaceutical company that provides end-to-end contract development and manufacturing services (CDMO), including GMP manufacturing of RNA, plasmid DNA, viral vectors, and cell therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zhejiang Innoforce Pharmaceuticals Comparables
Compare Zhejiang Innoforce Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| uBriGene Biosciences | 91% | |
| OBiO Technology | 84% | |
| GenScript | 83% |
For institutional investors. Book with your work email.
Zhejiang Innoforce Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 6, 2021 | ||||
| VC Round | Jun 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Zhejiang Innoforce Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CCIC Capital | Series A |
| Triwise Capital | Series A |
| 中南创投基金 | Series A |
| Advantech Capital | Series A |
| Quan Capital | Series A, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2025
Monthly visitors grew 650% MoM, reaching 885.
- Dec 6, 2021
$157M round led by 中南创投基金
For institutional investors. Book with your work email.
Zhejiang Innoforce Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zhejiang Innoforce Pharmaceuticals's valuation, stock price, and market status.
Is Zhejiang Innoforce Pharmaceuticals a public or private company?
Zhejiang Innoforce Pharmaceuticals is a private company.
What is the current stock price of Zhejiang Innoforce Pharmaceuticals?
Zhejiang Innoforce Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Zhejiang Innoforce Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zhejiang Innoforce Pharmaceuticals worth (valuation)?
Valuation information for Zhejiang Innoforce Pharmaceuticals is not publicly available.
Can I buy Zhejiang Innoforce Pharmaceuticals stock?
Zhejiang Innoforce Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zhejiang Innoforce Pharmaceuticals's last funding round?
Zhejiang Innoforce Pharmaceuticals's most recent funding round was Series A on December 6, 2021.
Who are the main investors in Zhejiang Innoforce Pharmaceuticals?
Key investors in Zhejiang Innoforce Pharmaceuticals include 中南创投基金, Quan Capital.
Will Zhejiang Innoforce Pharmaceuticals IPO soon?
No public IPO plans have been announced for Zhejiang Innoforce Pharmaceuticals.
How can I track Zhejiang Innoforce Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Zhejiang Innoforce Pharmaceuticals's shares on secondary markets.